NAMPT Inhibitors Market Size, Share, Trends, & Industry Analysis Report By Type of Molecule (Small Molecules and Biologics), By Phase, By Route of Administration, By Application, and By Region – Market Forecast, 2025–2034

The NAMPT inhibitors market size is expected to reach USD 5.52 Billion by 2034, according to a new study by Polaris Market Research. The report “NAMPT Inhibitors Market Size, Share, Trends, & Industry Analysis Report By Type of Molecule (Small Molecules and Biologics), By Phase, By Route of Administration, By Application, and By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The NAMPT inhibitors market is growing as pharmaceutical companies focus on developing new therapies targeting cellular energy metabolism. NAMPT is a key enzyme in the Nicotinamide Adenine Dinucleotide (NAD+) biosynthesis pathway, which supports cancer cell growth and survival. Inhibiting this enzyme helps limit energy supply to tumor cells, making them more vulnerable to treatment.

Ongoing clinical research and preclinical advancements are driving the adoption of NAMPT inhibitors across oncology pipelines. These inhibitors are explored as both standalone and combination therapies to improve treatment response. The growing interest from biotech and pharmaceutical firms, along with supportive regulatory pathways for targeted oncology drugs, is accelerating the market growth.

NAMPT Inhibitors Market Report Highlights

Based on type of molecule, the small molecules segment dominated the market share in 2024, due to its favorable pharmacokinetics, ease of formulation, and established role in oncology drug development.

In terms of phase, the preclinical segment dominated the market in 2024. This is owing to the early stage of most NAMPT inhibitor programs, as candidates undergo extensive in vitro and in vivo testing to evaluate efficacy, toxicity, and pharmacodynamic properties.

In terms of route of administration, the intravenous (IV) administration segment dominated the market in 2024, attributed to its ability to ensure controlled drug delivery, consistent bioavailability, and rapid systemic exposure.

Based on application, the hematology segment is projected to grow at the highest rate by 2034, driven by its expanding role in the treatment of blood cancers such as leukemia and lymphoma, supported by growing clinical research activity in this area.

North America accounted for the majority share in the global NAMPT inhibitors market in 2024, due to substantial investments in oncology research and early-phase drug discovery.

Asia Pacific is the fastest growing market, driven by the expanding regional biotech landscape and greater involvement in international research collaborations.

A few global key market players include AbbVie Inc., Angelini Pharma S.p.A., Antengene Therapeutics Limited, Aqualung Therapeutics Corporation, AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Calico LLC, FORMA Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline plc (GSK plc), Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Merck & Co., Inc., and Novartis AG.

Polaris Market Research has segmented the market report on the basis of type of molecule, phase, route of administration, application, and region:

By Type of Molecule Outlook (Revenue, USD Billion, 2020–2034)

Small Molecules

Biologics

By Phase Outlook (Revenue, USD Billion, 2020–2034)

Phase I

Phase II

Phase I/II

Preclinical

By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)

Oral

Intravenous

By Application Outlook (Revenue, USD Billion, 2020–2034)

Oncology

Hematology

Inflammatory and Metabolic Diseases

Neurology

Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more